Pharma BD Deal Intelligence
Teva's $3.4B Sicor acquisition delivered on its biosimilars entry strategy, giving the company injectable manufacturing capabilities it lacked—though FDA compliance failures at the acquired facilities, including propofol contamination recalls, undercut the operational payoff.
Injectable generics entry delivered initial growth but manufacturing quality issues emerged
Full analysis, sources & comparables →Teva Pharmaceutical agreed to acquire Sicor for $3.4 billion, gaining Sicor's expertise in generic injectable drugs and capabilities in duplicating the wave of…
Teva acquired Sicor for $3.4B for entry into biosimilars market.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Teva acquired Sicor for $3.4B for entry into biosimilars market.
Teva Pharmaceutical Industries closes acquisition/merger of Sicor Inc. for $3.4B, establishing strategic position and initiating integration.
Teva acquired Sicor for $3.4B gaining injectable capabilities but later faced FDA compliance issues including propofol contamination recalls from acquired facilities.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. (this deal) | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals | 2008 | $7.5B | 58 |
← Browse all deals · How we score deals
More: 2003 deals · Teva Pharmaceutical Industries Ltd. deals